Latest Regulatory Milestones News

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

EML Payments has appointed Adam Olding as its Global CEO, marking a pivotal step in its EML 2.0 transformation and signalling strengthened leadership to drive growth. Concurrently, regulatory developments around its Australian banking licence application introduce new compliance dynamics.

Boab Metals has received the crucial regulatory green light for its Sorby Hills project, clearing the way for full-scale mining operations and first concentrate production targeted in late 2027.

4DMedical has achieved CE Mark certification for its groundbreaking CT:VQ™ ventilation-perfusion imaging technology, unlocking the vast European market. The company also raised $83 million to fund rapid expansion across the EU.

Finder Energy has achieved a pivotal regulatory milestone with approval of the Development Area for its Kuda Tasi and Jahal oil fields, setting the stage for project sanction and a scalable production hub in Timor-Leste.

Winsome Resources Limited is set to be acquired by Li-FT Power Ltd through a scheme of arrangement, consolidating key lithium assets and creating a dual-listed entity on ASX and TSXV.

BCAL Diagnostics is expanding access to its Avantect pancreatic and ovarian cancer blood tests across Australia through partnerships with major pathology providers. This move marks a significant step in making early cancer detection more widely available.

Native Mineral Resources has successfully poured 560 ounces of gold doré at its Blackjack plant and is on track to begin mining at Podosky in April, advancing multiple projects in Queensland.

Brazilian Rare Earths Limited has secured a key Trial Mining Licence for its Monte Alto project, marking a significant step toward commercial rare earths production in Brazil.

Clarity Pharmaceuticals has signed a significant manufacturing supply agreement with Theragenics to produce copper-64, a key isotope for its upcoming prostate cancer diagnostic, Cu-SAR-bisPSMA. This deal strengthens Clarity’s US supply network ahead of anticipated FDA approval and commercial launch.

Nickel Industries has secured a significant increase in its 2026 ore sales license and finalized a long-term supply agreement for its Excelsior Nickel Cobalt project, enhancing production certainty and sustainability.

Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.